Wound healing delay after central venous access following DCF/VEGF-trap therapy.
Hypertension, proteinuria, thromboembolic or bleeding events are well-recognized complications occurring while targeting VEGF pathway. Wound healing dysfunctions have also been described in patients undergoing major surgery. For the first time, we report wound healing delay after central venous access following DCF-VEGF-Trap. VEGF-Trap may affect both angiogenesis and reepithelialization which are necessary to the normal repair process.
Ferté
Charles
C
Department of Medicine, Institut Gustave Roussy, Phase I unit (SITEP), 94805, Villejuif, France. chferte@hotmail.com
Massard
Christophe
C
Moldovan
Christian
C
Desruennes
Eric
E
Loriot
Yohann
Y
Soria
Jean-Charles
JC
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D062905:Central Venous Catheters / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D000077143:Docetaxel; D005472:Fluorouracil / Q000009:adverse effects*; D006801:Humans; D008297:Male; D040262:Receptors, Vascular Endothelial Growth Factor / Q000009:adverse effects*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects*; D043823:Taxoids / Q000009:adverse effects*; D014945:Wound Healing
D011993:Recombinant Fusion Proteins; D043823:Taxoids; C533178:aflibercept; D000077143:Docetaxel; D040262:Receptors, Vascular Endothelial Growth Factor; D002945:Cisplatin; D005472:Fluorouracil